Intrinsically magnetic hydroxyapatite

Patent metadata

Field	Value
Publication number	US-9327027-B2
Application number	US-201113812741-A
Country	US
Kind code	B2
Filing date	Jul 28, 2011
Priority date	Jul 29, 2010
Publication date	May 3, 2016
Grant date	May 3, 2016

Abstract

The present invention relates to hydroxyapatite doped with Fe 2+ ions and Fe 3+ ions which partially substitute the calcium ions in the crystal lattice. The hydroxyapatite is characterized by an intrinsic magnetism of 0.05 to 8 emu/g, measured by applying a magnetic field of 34 Oe, due to the presence of magnetic nano-domains in the crystal lattice of HA, given the limited amount of magnetic secondary phases present, less than about 3% by volume.
The intrinsically magnetic hydroxyapatite can be loaded with biological substances selected in the group consisting of proteins, genes, stem cells, growth factors, vascularization factors, active substances and drugs, under the control of an external magnetic field, as a carrier and release agent for biological substances or drugs, as a contrast agent in diagnostics or for bone or osteocartilage regeneration.

First claim

The invention claimed is:

1. A hydroxyapatite comprising calcium ions and phosphate ions in a crystal lattice, characterized in that it is doped with Fe 2+ ions and Fe 3+ ions, said Fe 2+ and said Fe 3+ being inside said crystal lattice and partially substituting said calcium ions in said crystal lattice in a quantitative ratio Fe 3+ /Fe 2+ of 1 to 4, has magnetism of 0.05 to 8 emu/g, measured by applying a magnetic field of 34 Oe, due to the presence of magnetic nano-domains in the lattice of hydroxyapatite, and comprises an amount of secondary magnetic phases below about 3 vol %.

2. The hydroxyapatite according to claim 1 , wherein said magnetism is of 0.1 to 5 emu/g, recorded by applying a magnetic field of 34 Oe.

3. The hydroxyapatite according to claim 1 or 2 , wherein said ratio Fe 3+ /Fe 2+ is of 2 to 3.5.

4. The hydroxyapatite according to claim 1 , comprising an amount of secondary magnetic phases≦2 vol %.

5. The hydroxyapatite according to claim 1 , having a ratio (Fe+Ca)/P of 1.5 to 1.9.

6. The hydroxyapatite according to claim 1 , in the form of nanoparticles having a width of 5-30 nm and a length up to 150 nm, or in the form of aggregates of said nanoparticles.

7. The hydroxyapatite according to claim 6 , wherein said nanoparticles comprise spherical voids of 2-5 nm.

8. The hydroxyapatite according to claim 1 , loaded with biological substances selected in the group consisting of proteins, genes, stem cells, growth factors and vascularization factors.

9. A biomimetic bone or osteocartilage substitute comprising a hydroxyapatite according to claim 1 .

10. A method of treating or diagnosis a medical condition comprising the steps of providing the hydroxyapatite according to claim 1 and loading the hydroxyapatite with one or more biological substances or drugs and using the loaded hydroxyapatite as a carrier and release agent for said one or more biological substances or drugs or as a contrast agent for diagnosis or as material for bone or osteocartilage regeneration.

11. The method according to claim 10 , wherein said loaded hydroxyapatite is used as a carrier and release agent for said one or more biological substances or drugs.

12. The method according to claim 10 , wherein said loaded hydroxyapatite is used as a contrast agent in diagnostics.

13. The method according to claim 10 , wherein said loaded hydroxyapatite is use as a material for bone or osteocartilage regeneration.

14. A method for preparing the hydroxyapatite according to claim 1 , comprising the following steps:
a) adding a solution comprising Fe(II) and Fe(III) ions to a suspension/solution containing Ca(II) ions;
b) adding a solution of phosphate ions to the suspension/solution of step a);
c) heating the suspension/solution of step b) to a temperature of 15° to 80° C.;
d) separating a precipitate from mother liquors obtained in step c) to obtain the hydroxyapatite according to claim 1 .

15. A method according to claim 14 , wherein said solution of phosphate ions is added to the suspension/solution containing Ca(II) ions and iron ions in a period of 1-3 hours.

16. A method according to claim 14 , wherein after adding phosphate ions, the ratio of iron ions with respect to calcium ions is adjusted by further adding of a solution of iron ions so as to obtain a molar ratio Fe/Ca of 5 to 30mol %.

17. A method according to claim 14 , wherein said Fe(II) and Fe(III) ions derive from FeCl 2 and FeCl 3 , respectively.

18. A method according to claim 14 , wherein said Ca(II) ions derive from calcium hydroxide, calcium nitrate, calcium acetate, calcium carbonate or combinations thereof.

19. A method according to claim 14 , wherein said phosphate ions derive from phosphoric acid.

20. The hydroxyapatite according to claim 1 , loaded with active substances or drugs.

21. The hydroxyapatatite according to claim 1 , in a form of nanoparticles having a width of 10-20 nm.

22. The hydroxyapatite according to claim 1 , in a form of nanoparticles having a length of 80-150 nm.

Assignees

• Tampieri Anna
• Landi Elena
• Sandri Monica
• Pressato Daniele
• Rivas Rey José
• Banobre López Manuel
• Marcacci Maurilio
• Consiglio Nazionale Ricerche
• Univ Santiago Compostela
• Fin Ceramica Faenza Spa

Inventors

• Tampieri Anna
• Landi Elena
• Sandri Monica
• Pressato Daniele
• Rivas Rey José
• Banobre López Manuel
• Marcacci Maurilio

Classifications

• C01B25/322

  Preparation by neutralisation of orthophosphoric acid · CPC title

• A61L2430/06

  for cartilage reconstruction, e.g. meniscus · CPC title

• A61L2430/02

  for reconstruction of bones; weight-bearing implants · CPC title

• A61K49/08

  characterised by the carrier · CPC title

• C01B25/45

  containing plural metal, or metal and ammonium · CPC title